Parallel Advisors’s Nuvation Bio NUVB Stock Holding History

Parallel Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.3K	Hold	7,622	–	–	﹤0.01%	2236
2026 Q1	$32.7K	Sell	7,622 -272	-3%	-$1.51K	﹤0.01%	2233
2025 Q4	$70.7K	Buy	7,894 +297	+4%	+$1.84K	﹤0.01%	1653
2025 Q3	$28.1K	Buy	7,597 +2,597	+52%	+$7.08K	﹤0.01%	2085
2025 Q2	$9.75K	Sell	5,000 -92	-2%	-$192	﹤0.01%	2489
2025 Q1	$8.96K	Buy	+5,092	New	+$11.6K	﹤0.01%	2477
2023 Q1	–	Sell	-866	Closed	-$1.66K	–	3480
2022 Q4	$1.66K	Buy	866 +761	+725%	+$1.54K	﹤0.01%	2754
2022 Q3	$0	Buy	+105	New	+$300	﹤0.01%	3380

Other funds holding NUVB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Algert Global San Francisco, California $8.43B AUM 80.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Parallel Advisors's NUVB Position: Q2 2026 in Review

Parallel Advisors held its Nuvation Bio (NUVB) position steady in Q2 2026 at 7,622 shares worth $43.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2236.

Parallel Advisors first reported a position in NUVB in Q3 2022 and has held it in 8 quarters since. The position peaked at $70.7K in Q4 2025. 165 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

Parallel Advisors held 7,622 shares of Nuvation Bio worth $43.3K as of Q2 2026.
Parallel Advisors left its Nuvation Bio share count unchanged in Q2 2026.
Nuvation Bio made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2236 holding.
Parallel Advisors first reported a position in Nuvation Bio in Q3 2022 and has held it in 8 quarters since.
Parallel Advisors's Nuvation Bio position peaked at $70.7K in Q4 2025.
165 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.